Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VUM02 + BAT
- Development stage
- Unknown
- Lead developer
- Vcanbiopharma
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
VUM02 + BAT refers to a clinical combination regimen consisting of the **PSMA-targeted radiopharmaceutical VUM02** (typically utilized as the PET tracer [18F]VUM02) and **Bipolar Androgen Therapy (BAT)**. VUM02 is a small-molecule ligand developed at Vanderbilt University that binds with high affinity to the **prostate-specific membrane antigen (PSMA)**, a cell-surface protein significantly overexpressed in prostate cancer. Bipolar Androgen Therapy is a treatment strategy for metastatic castration-resistant prostate cancer (mCRPC) that involves the rapid cycling of serum testosterone levels between supraphysiologic and castrate concentrations, typically achieved through high-dose **testosterone** (e.g., testosterone cypionate) administration. In this combination, VUM02 serves as a diagnostic imaging biomarker to monitor the biological response of the tumor to the hormonal fluctuations induced by BAT, allowing researchers to assess changes in PSMA expression and tumor burden in real-time.
- Other names
- [18F]VUM02 + Bipolar Androgen TherapyVUM02 + Bipolar Androgen Therapy
02
Targets
PSMA (Prostate-specific membrane antigen)AR (Adrenergic receptors)
Beyond the preview
Go deeper on VUM02 + BAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VUM02 + BAT.